AArkstore enterprise Aarkstore - Hyperlipidemia - Pipeline Review, H2 2014
Browse Full Report @ http://www.aarkstore.com/pharmaceuticals-healthcare/63089/hyperlipidemia-pipelinereview
Published: Oct 2014 | 163 Pages PDF : $ 2000 | Site Licence: $ 4000 | Enterprise Wide Licence : $ 6000
Summary ‘Hyperlipidemia - Pipeline Review, H2 2014’, provides an overview of the Hyperlipidemia’s therapeutic pipeline. This Market Research Report provides comprehensive information on the therapeutic development for Hyperlipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperlipidemia and special features on late-stage and discontinued projects.
AArkstore enterprise Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hyperlipidemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hyperlipidemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
AArkstore enterprise - Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Order full Report with TOC and Sample page visit: http://www.aarkstore.com/pharmaceuticals-healthcare/63089/hyperlipidemia-pipelinereview
Table of Contents: Introduction 7 Global Markets Direct Report Coverage 7 Hyperlipidemia Overview 8 Therapeutics Development 9 Pipeline Products for Hyperlipidemia - Overview 9 Pipeline Products for Hyperlipidemia - Comparative Analysis 10 Hyperlipidemia - Therapeutics under Development by Companies 11 Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes 14 Hyperlipidemia - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 Hyperlipidemia - Products under Development by Companies 17 Hyperlipidemia - Products under Investigation by Universities/Institutes 20 Hyperlipidemia - Companies Involved in Therapeutics Development 21 ACROVIS biostructures GmbH 21 Advinus Therapeutics Ltd. 22 Angion Biomedica Corp. 23 BiOrion Technologies B.V. 24
AArkstore enterprise Celgene Corporation 25 Digna Biotech, S.L. 26 FibroGen, Inc. 27 Galectin Therapeutics, Inc. 28 Genfit SA 29 GenKyoTex S.A. 30 Gilead Sciences, Inc. 31 GNI Group Ltd. 32 La Jolla Pharmaceutical Company 33 LG Life Sciences, Ltd. 34 Nitto Denko Corporation 35 Pfizer Inc. 36 List Of Tables Number of Products under Development for Hyperlipidemia, H2 2014 12 Number of Products under Development for Hyperlipidemia - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Development by Companies, H2 2014 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2014 17 Comparative Analysis by Clinical Stage Development, H2 2014 18 Comparative Analysis by Early Stage Development, H2 2014 19 Products under Development by Companies, H2 2014 20 Products under Development by Companies, H2 2014 (Contd..1) 21 Products under Development by Companies, H2 2014 (Contd..2) 22 List Of Figures Number of Products under Development for Hyperlipidemia, H2 2014 12 Number of Products under Development for Hyperlipidemia - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 14 Number of Products under Investigation by Universities/Institutes, H2 2014 17 Comparative Analysis by Clinical Stage Development, H2 2014 18 Comparative Analysis by Early Stage Products, H2 2014 19 Assessment by Monotherapy Products, H2 2014 48 Number of Products by Top 10 Targets, H2 2014 49 Number of Products by Stage and Top 10 Targets, H2 2014 50 Number of Products by Top 10 Mechanism of Actions, H2 2014 51
AArkstore enterprise Related Market Research reports: •
Corticosteroid-Responsive Dermatoses - Pipeline Review, H1 2014
•
Hematological Tumor - Pipeline Review, H1 2014
•
Inflammation - Pipeline Review, H1 2014
•
Opioid Induced Side Effects - Pipeline Review, H1 2014
•
Skin Infections - Pipeline Review, H1 2014
•
Restenosis - Pipeline Review, H1 2014
•
Tauopathies - Pipeline Review, H1 2014
•
Nasopharyngitis (Common Cold) - Pipeline Review, H1 2014
•
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H1 2014
•
Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2014
About Aarkstore Enterprise Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers Contact Details: Aarkstore Enterprise Phone: +91 9987295242 / 022-27564953 Email: enquiry@aarkstore.com Our Website: http://www.aarkstore.com Our Blog : http://www.aarkstore.com/blog/ Latest News : http://www.aarkstore.com/news Facebook: https://www.facebook.com/aarkstoredotcom
AArkstore enterprise